BACKGROUND: Recent advances in the immunotherapeutic treatment of cancer have led to the development of multiple new directed therapies including monoclonal antibodies that block the immune checkpoint T-cell receptor programmed death 1 (PD-1) and the PD-1 ligand, programmed death ligand 1 (PD-L1). Various immune-related toxicities have been associated with these drugs including, most commonly, skin rashes. METHODS: Five cases of lichenoid dermatitis, including one case of lichenoid mucositis and one case of lichen sclerosus, associated with anti-PD-L1 and anti-PD1 therapy were compared with three biopsies of non-drug-related lichen planus (LP) and three lichen planus-like keratoses (LPLK) used as controls. RESULTS: Histopathologic and immunophenotypic analysis of these lichenoid lesions demonstrated significantly greater histiocytic infiltrates than observed in control lichenoid reactions (p = 0.0134). We also observed increased spongiosis and epidermal necrosis. No significant differences were seen in expression of CD3, CD4:CD8, CD20, PD-1, CD25, Foxp3, CXCL13 and PD-L1 expression. CONCLUSIONS: These findings expand the literature of immune-related toxicities of PD-L1 and PD-1 blockade to include lichenoid dermatitis and lichenoid mucositis. Of note, these cutaneous side effects were amenable to topical treatment, without the need for medication dose reduction or discontinuation.
BACKGROUND: Recent advances in the immunotherapeutic treatment of cancer have led to the development of multiple new directed therapies including monoclonal antibodies that block the immune checkpoint T-cell receptor programmed death 1 (PD-1) and the PD-1 ligand, programmed death ligand 1 (PD-L1). Various immune-related toxicities have been associated with these drugs including, most commonly, skin rashes. METHODS: Five cases of lichenoid dermatitis, including one case of lichenoid mucositis and one case of lichen sclerosus, associated with anti-PD-L1 and anti-PD1 therapy were compared with three biopsies of non-drug-related lichen planus (LP) and three lichen planus-like keratoses (LPLK) used as controls. RESULTS: Histopathologic and immunophenotypic analysis of these lichenoid lesions demonstrated significantly greater histiocytic infiltrates than observed in control lichenoid reactions (p = 0.0134). We also observed increased spongiosis and epidermal necrosis. No significant differences were seen in expression of CD3, CD4:CD8, CD20, PD-1, CD25, Foxp3, CXCL13 and PD-L1 expression. CONCLUSIONS: These findings expand the literature of immune-related toxicities of PD-L1 and PD-1 blockade to include lichenoid dermatitis and lichenoid mucositis. Of note, these cutaneous side effects were amenable to topical treatment, without the need for medication dose reduction or discontinuation.
Authors: Charles Kyung Min Lee; Shufeng Li; Duy Cong Tran; Gefei Alex Zhu; Jinah Kim; Bernice Y Kwong; Anne Lynn S Chang Journal: J Am Acad Dermatol Date: 2018-05-29 Impact factor: 11.527
Authors: Veronica J Shi; Nemanja Rodic; Scott Gettinger; Jonathan S Leventhal; Julia P Neckman; Michael Girardi; Marcus Bosenberg; Jennifer N Choi Journal: JAMA Dermatol Date: 2016-10-01 Impact factor: 10.282
Authors: Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller Journal: Curr Treat Options Oncol Date: 2020-03-19
Authors: Genevieve J Kaunitz; Manisha Loss; Hira Rizvi; Sowmya Ravi; Jonathan D Cuda; Karen B Bleich; Jessica Esandrio; Inbal Sander; Dung T Le; Luis A Diaz; Julie R Brahmer; Charles G Drake; Travis J Hollmann; Mario E Lacouture; Matthew D Hellmann; Evan J Lipson; Janis M Taube Journal: Am J Surg Pathol Date: 2017-10 Impact factor: 6.394
Authors: Bernardo Leon Rapoport; Ronwyn van Eeden; Vincent Sibaud; Joel B Epstein; Jean Klastersky; Matti Aapro; Devan Moodley Journal: Support Care Cancer Date: 2017-07-13 Impact factor: 3.603
Authors: V Sibaud; C Eid; V R Belum; P Combemale; B Barres; L Lamant; L Mourey; C Gomez-Roca; C L Estilo; R Motzer; E Vigarios; M E Lacouture Journal: J Eur Acad Dermatol Venereol Date: 2017-05-08 Impact factor: 6.166